CSL Limted (CSL)

  • By Carole Ann Furman

  • June 12, 2015
  • 7:16 am BST

CSL Limited on the ASX Stock Exchange

Access the latest stock market reports on CSL Limited (CSL) at the bottom of the page.

Is it time to Buy, Sell or Hold CSL Limited Stocks?

CSL Limited is one of the world’s largest suppliers of blood products and vaccines with operations covering plasma services, biosciences, pharmaceuticals and human vaccines. The major areas of business operations for CSL are:

  • CSL Biotherapies
  • CSL Bioplasma &
  • CSL Behring

CSL biotherapies manufactures and markets biological products for human use along with various prescription pharmaceuticals to treat a multitude of human medical ailments both in Australia and abroad.

CSL bioplasma concentrates its business efforts on treating bleeding disorders like haemophilia, infections and autoimmune diseases, treating blood disorders among newborns and specialises in the treatment of severe blood loss and acute burns.

CSL Behring covers a wide range of beneficial services relating to plasma derived products that are truly life-saving. CSL behring treats people with haemophilia and similar bleeding disorders, immune deficiency disorders, the prevention of haemolytic diseases in newborns, cardiac surgery patients and shock and burn victims.

CSL Limited Quick Facts (as of June 2015)

  • Chairman: Prof. John Shine AO
  • CEO: Mr Paul Roger Perreault
  • Industry Group: Pharmaceuticals, Biotechnology & Life Sciences
  • Shares on issue: 466,510,206
  • Market Cap: Over $40 Billion
  • www.csl.com.au

Return to ASX Top 20 Stocks